Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

T-Cell Engager Set For Pivotal GI Trial

 
• By Dexter Jie Yan
  
The CDH17 race has been becoming tighter since 2022, when Arbele took its first candidate against the target into the clinic. (Shutterstock)

More from Interviews

More from Focus On Asia